Spirometry quality in patients with COPD exacerbation, related to the frequent exacerbator phenotype

Similar documents
Lung Function Basics of Diagnosis of Obstructive, Restrictive and Mixed Defects

This is a cross-sectional analysis of the National Health and Nutrition Examination

Spirometric protocol

Confirmatory spirometry for adults hospitalized with a diagnosis of asthma or chronic obstructive pulmonary disease exacerbation

Int. J. Pharm. Sci. Rev. Res., 34(2), September October 2015; Article No. 24, Pages: Role of Spirometry in Diagnosis of Respiratory Diseases

Chronic Obstructive Pulmonary Disease (COPD) Clinical Guideline

Pulmonary Function Testing

Guideline for the Diagnosis and Management of COPD

Course Handouts & Disclosure

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Impact of the new ATS/ERS pulmonary function test interpretation guidelines

Relationship between Methacholine Challenge Testing and exhaled Nitric Oxide in adult patients with suspected bronchial asthma

COPD. Breathing Made Easier

Is there any correlation between the ATS, BTS, ERS and GOLD COPD s severity scales and the frequency of hospital admissions?

C hronic obstructive pulmonary disease (COPD) is one of

Clinical and radiographic predictors of GOLD-Unclassified smokers in COPDGene

Office Based Spirometry

Occupational exposures are associated with worse morbidity in patients with COPD

Assessment of Bronchodilator Response in Various Spirometric Patterns

SPIROMETRY TECHNIQUE. Jim Reid New Zealand

QUALITY OF LIFE MEASURED BY THE ST GEORGE'S RESPIRATORY QUESTIONNAIRE AND SPIROMETRY

Title: Objective measurement of cough frequency during COPD exacerbation convalescence

Management of Acute Exacerbations

Diagnostic value of post-bronchodilator pulmonary function testing to distinguish between stable, moderate to severe COPD and asthma

Epidemiology of COPD Prof. David M. Mannino, M.D.

Decramer 2014 a &b [21]

Productivity losses in chronic obstructive pulmonary disease a population-based survey.

Autologous Stem Cell Therapy & its Effects on COPD:

Understanding the Basics of Spirometry It s not just about yelling blow

Prevalence of undetected persistent airflow obstruction in male smokers years old

DATE: 09 December 2009 CONTEXT AND POLICY ISSUES:

Systematic Review of Early Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease (COPD) in Family Practice

Defining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist

THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable

Mood disorders in elderly patients hospitalized for acute exacerbation of COPD

Using Pay-for-Performance to Improve COPD Care MHC64474 SV64474

Turning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital

How to treat COPD? What is the mechanism of dyspnea? Smoking cessation

Differential diagnosis

COPD. Helen Suen & Lexi Smith

Cigarette Smoking and Lung Obstruction Among Adults Aged 40 79: United States,

COPD: From Hospital to Home October 5, 2015 Derek Linderman, MD Associate Professor COPD Center Pulmonary Nodule Clinic

Chronic obstructive pulmonary disease

Importance of fractional exhaled nitric oxide in diagnosis of bronchiectasis accompanied with bronchial asthma

UNIT TWO: OVERVIEW OF SPIROMETRY. A. Definition of Spirometry

COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis.

COPD: A Renewed Focus. Disclosures

ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss?

Comparison between Spirometry and BODE Index for Clinical Assessment in Chronic Obstructive Pulmonary Disease Patients

Disclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to:

Community COPD Service Protocol

The role of blood eosinophil level in acute exacerbation of Chronic Obstructive Pulmonary Disease

Bronchodilator responsiveness in patients with COPD

2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters

Assessment of reversibility of airway obstruction. disease. in patients with chronic obstructive airways. FEVy after salbutamol occurred in the

UNDERSTANDING COPD MEDIA BACKGROUNDER

Asthma Tutorial. Trainer MRW. Consider the two scenarios, make an attempt at the questions, what guidance have you used?

Relationship Between FEV1& PEF in Patients with Obstructive Airway Diseases

Evaluation of efficacy and utility of spirometry data in elderly

Bode index as a predictor of severity in patients with chronic obstructive pulmonary disease.

Chronic Obstructive Pulmonary Diseases:

S P I R O M E T R Y. Objectives. Objectives 3/12/2018

Coexistence of confirmed obstruction in spirometry and restriction in body plethysmography, e.g.: COPD + pulmonary fibrosis

C hronic obstructive pulmonary disease (COPD) is one of

Asthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research

Chronic Obstructive Pulmonary Disease

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

CIRCULAR INSTRUCTION REGARDING ESTABLISHMENT OF IMPAIRMENT DUE TO OCCUPATIONAL LUNG DISEASE FOR THE PURPOSES OF AWARDING PERMANENT DISABLEMENT

T he prevalence of chronic obstructive pulmonary

Study Shows Positive Benefits Of Cellular Therapy For COPD Patients

TORCH: Salmeterol and Fluticasone Propionate and Survival in COPD

Exacerbations of COPD. Dr J Cullen

COMORBIDITIES AS AN ELEMENT OF MULTIDIMENSIONAL PROGNOSTIC ASSESSMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Outline FEF Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications?

What do pulmonary function tests tell you?

Evaluating Spirometric Trends in Cystic Fibrosis Patients

AECOPD: Management and Prevention

Asthma COPD Overlap (ACO)

Chronic Obstructive Pulmonary Disease (COPD).

รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น

Spirometry: Introduction

Relevant Papers: eight relevant articles were found, but four were reviewed because they were most directly related to the topic

COPD exacerbation. Dr. med. Frank Rassouli

Spirometry is the most frequently performed. Obstructive and restrictive spirometric patterns: fixed cut-offs for FEV1/FEV6 and FEV6

COPD: Current Medical Therapy

Over the last several years various national and

Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015

THE PHARMA INNOVATION - JOURNAL Clinical Characteristics of Chronic Obstructive Pulmonary Disease

Page 126. Type of Publication: Original Research Paper. Corresponding Author: Dr. Rajesh V., Volume 3 Issue - 4, Page No

COPD in Korea. Division of Pulmonary, Allergy and Critical Care Medicine of Hallym University Medical Center Park Yong Bum

Getting Spirometry Right It Matters! Performance, Quality Assessment, and Interpretation. Susan Blonshine RRT, RPFT, AE-C, FAARC

COPD UPDATE ıdr Shitrit David ıhead of the Pulmonary Department ımeir Medical Center

Anyone who smokes and/or has shortness of breath and sputum production could have COPD

Spirometry: an essential clinical measurement

Using Spirometry to Rule Out Restriction in Patients with Concomitant Low Forced Vital Capacity and Obstructive Pattern

Spirometry in primary care

Roflumilast (Daxas) for chronic obstructive pulmonary disease

Spirometry: FEVER DISEASE DIABETES HOW RELIABLE IS THIS? 9/2/2010 BUT WHAT WE PRACTICE: Spirometers are objective tools

To describe the impact of COPD exacerbations and the importance of the frequent exacerbator phenotype.

Spirometric Standards and Patient Characteristics: An Exploratory Study of Factors Affecting Fulfillment in Routine Clinical Practice

Transcription:

Spirometry quality in patients with COPD exacerbation, related to the frequent exacerbator phenotype Calitatea spirometriei la pacienții cu exacerbare de BPOC, legată de fenotipul exacerbator frecvent Irina Strâmbu 1,,, Alina Croitoru 1,,, Ileana Stoicescu 1,, Mădălina Burecu 1,, Daniela Dospinoiu, Camelia Niță, Felicia Cojocaru, Diana Ioniță, Marius Nasta Institute of Pneumophtisiology, Elias Emergency University Hospital, Arensia Exploratory Medicine, Carol Davila University of Medicine and Pharmacy, Corresponding author: Alina Croitoru, E-mail: haulicaalina@yahoo.com Abstract Aim. The study aims to assess the quality of spirometry sessions in patients with chronic obstructive pulmonary disease (COPD) exacerbation, to compare the spirometry quality in patients with frequent exacerbations (two or more in the previous year) and in patients without exacerbations. Subjects and method. Consecutive COPD patients with moderate infectious exacerbation were evaluated at presentation. The quality of spirometry (ATS/ERS 00: at least three acceptable curves with repeatable values for FVC and FEV1) and the time needed to obtain a spirometry session were evaluated and compared to the spirometries obtained - months before, in a stable period. Results. Eighty COPD patients were evaluated, mean age was years old, 0 males. Although all patients had valid spirometry sessions in the stable period, 1 subjects (1%) could not obtain a valid session during exacerbation due to cough, shortness of breath and/or fatigue. More efforts were necessary to obtain a spirometry session during exacerbation (.±1. efforts) compared to the stable period (.±0. efforts, p=0.001). The time needed to obtain a spirometry session was significantly higher in exacerbation (.±1. minutes) compared to the stable period (.±1., p=0.001). Frequent exacerbators ( patients; 1%) had similar spirometry quality in exacerbation and in the stable period, and similar amount of time needed to perform the spirometries compared to the patients with no exacerbations (p>0.0). Conclusions. Good spirometry quality could be obtained in % of patients, and a longer period needed to obtain a spirometry session was seen in exacerbation compared to a stable COPD period. Similar spirometry quality was seen in patients with frequent exacerbations, as in patients without exacerbations in the previous year. Keywords: COPD, exacerbation, spirometry Rezumat Scop. Studiul își propune să evalueze calitatea sesiunilor de spirometrie la pacienții care prezintă o exacerbare de bronhopneumopatie obstructivă cronică (BPOC), să compare calitatea spirometriei la pacienții cu exacerbări frecvente (două sau mai multe în anul precedent) și la pacienții fără exacerbări. Subiecți și metodă. Pacienți consecutivi cu exacerbare infecțioasă moderată de BPOC au fost evaluați la prezentare. Calitatea spirometriei (ATS/ERS 00: cel puțin trei curbe acceptabile cu valori repetabile pentru FVC și FEV1) și timpul necesar pentru obținerea unei sesiuni de spirometrie au fost evaluate și comparate cu spirometriile obținute cu - luni înainte într-o perioadă stabilă. Rezultate. Au fost evaluați 0 de pacienți cu BPOC, vârsta medie de ani, 0 de bărbați. Deși toți pacienții au avut sesiuni de spirometrie valabile în perioada stabilă, 1 subiecți (1%) nu au putut obține o sesiune valabilă în timpul exacerbării din cauza tusei, a dispneei și/sau a oboselii. Mai multe eforturi au fost necesare pentru a obține o sesiune de spirometrie în timpul exacerbării (,±1, eforturi) comparativ cu perioada stabilă (,±0, eforturi, p=0,001). Timpul necesar pentru obținerea unei sesiuni de spirometrie a fost semnificativ mai mare în timpul exacerbării (,±1, minute) comparativ cu perioada stabilă (,±1,, p=0,001). Exacerbatorii frecvenți ( de pacienți; 1%) au avut o calitate similară a spirometriei în exacerbare și în perioada stabilă și o perioadă similară de timp necesară efectuării spirometriei în comparație cu pacienții fără exacerbări (p>0,0). Concluzii. La % dintre pacienți ar putea fi obținută o calitate bună a spirometriei, iar în exacerbarea BPOC comparativ cu o perioadă stabilă a fost observat un timp mai îndelungat necesar pentru obținerea unei sesiuni de spirometrie. Calitatea spirometrică a fost similară la pacienții cu exacerbări frecvente şi la pacienții fără exacerbări în anul precedent. Cuvinte-cheie: BPOC, exacerbare, spirometrie Introduction Chronic obstructive pulmonary disease (COPD) is a widespread disease generally related to smoking, characterized by chronic progressive and irreversible obstruction of the airways. The prevalence of COPD is estimated at.%. Figures may vary according to the diagnostic procedures used: patient reported diagnosis.%, physician diagnosis.1%, diagnosis by spirometry.1% (1). Acute exacerbations of COPD are considered important and deleterious events in the course of the disease, accounting for decreased quality of life, accelerated drop in the lung function and increased mortality (). COPD patients experience 0.-. exacerbations per year, according to different surveys. In 00, a number of,00 hospital admissions were recorded for COPD exacerbations in US (). According to Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommendations, functional respiratory testing is essential for the correct diagnosis and staging in COPD patients (). In current clinical practice, only about a third of the patients diagnosed with COPD VOL. No. /01

Pneumologia REVISTA SOCIETĂŢII ROMÂNE DE PNEUMOLOGIE have an accurate spirometry related to their diagnosis, as demonstrated by a Swedish study (). Patients are sometimes diagnosed for the first time with COPD during a hospital visit for an acute exacerbation. Even though it is recognized that spirometry is essential for proving the obstruction and staging, usually clinicians are reluctant to perform a spirometry during an exacerbation. A low quality of the tests is expected due to worsened clinical status and reluctance of patients to perform the efforts needed for spirometry when they feel worse. The exploration of the respiratory function can give valuable information about the presence of obstructive syndrome and its severity, allowing the design of a correct management plan and avoiding misdiagnosis. Respiratory function is directly linked to the risk of mortality and hospital admission. In a study by Anthonisen, the overall mortality over years was a mean of % in patients admitted for acute exacerbations of COPD, patients with FEV1<0% having a significantly higher mortality rate than patients with FEV1 > 0% predicted, who had a mortality similar to that of healthy smokers (). However, this is not the only parameter that can evaluate the severity of COPD. The 01 GOLD update () proposed a combined assessment of COPD severity according to functional impairment, severity of symptoms and exacerbation history. Some COPD patients have typically few exacerbations (less than two per year), while others, called frequent exacerbators, have two or more exacerbations per year, this being correlated with a worse prognosis and higher mortality (). The aim of this study was to evaluate whether good quality spirometries can be performed in COPD patients during an acute exacerbation, and if the quality of the tests could be correlated to the status of frequent exacerbator of the patients. We aimed to assess the quality of the spirometry sessions in patients presenting with COPD exacerbations. In addition, we compared the quality of spirometry in COPD patients with previous frequent exacerbations (two or more in the previous year) with those performed in COPD patients without exacerbations. Materials and method This was a prospective, observational study, on consecutive COPD patients with an exacerbation, performed in ARENSIA research unit within the Marius Nasta Institute of Pneumophtisiology, Bucharest, over a oneyear period. The patients were included in the study on the occasion of the preselection for a randomized clinical trial aiming to determine treatment for COPD exacerbation. For this observational study, only information from the preselection visit and medical history was used, without interfering with the conduct and the data of the randomized clinical trial. Subjects: 0 patients with COPD who had an episode of moderate exacerbation and presented in the pulmonology department were included in this study. All patients had a previous diagnosis of COPD for at least months and, at the moment of the exacerbation, were receiving maximal bronchodilator treatment as recommended by a pulmonologist. The exacerbation was defined according to Anthonisen criteria, as an increase in cough, sputum volume and purulence, and worsening of dyspnea (). The inclusion criteria were: age between 0-0 years old, history of smoking (at least PA), previous diagnosis of COPD stage II-IV GOLD confirmed by spirometry (obstructive syndrome: FEV1/FVC ratio <0.). The exclusion criteria were: severe exacerbation requiring ventilatory support, severe respiratory acidosis (ph<.), abnormalities on chest X-ray (e.g., pneumonia, pneumothorax, lung tumors, tuberculosis), history of malignancies in the past years, long-term oxygen therapy. The patients consented in writing to participate to the study. The evaluated parameters were spirometry quality and the time required to obtain a spirometry session. Spirometry was performed using a Vitalograph spirometer. The spirometries were performed in the first day of presentation to the clinic, before the initiation of any treatment for the exacerbation. The tests were postbronchodilator, after the administration of 00 mcg of inhaled salbutamol. At least three tests were performed, observing the acceptability criteria for performance and repeatability. The test was stopped if criteria were not fulfilled in consecutive efforts. The quality of spirometry was assessed using the ATS/ERS 00 criteria (,,11) : at least three acceptable values with repeatable curves for forced vital capacity (FVC) and forced expiratory volume in 1 second (FEV1). A spirometry test was considered acceptable if it included at least three efforts without artifacts, an expiration duration of at least seconds or plateau before seconds. The tests were considered reproducible if the difference between the two highest FEV1 and FVC values were both less than 10 ml. The time needed to obtain all acceptable spirometries was recorded for each patient. Functional respiratory parameter values measured in this session were compared to those obtained - months earlier, when the patients were in a stable COPD period. Statistical analysis. For statistical analysis, the SPSS version 1.0 was used. The results were expressed as mean values ± standard deviation. For variable normality analysis, the Shapiro-Wilk test was used. The parameters comparison was made with the Student s t-test. A p value < 0.0 was considered significant. Results Eighty patients with mild/moderate COPD exacerbation were included in the study. The mean age was years old. Most patients were men (0 patients). All patients had at least one valid spirometry performed - months prior to the moment of exacerbation, recorded in the database of the Research center. VOL. No. /01

p=0.001 p=0.001 Number of efforts Time (minutes) 1 0 Stability period 0 During exacerbation 0 Stability period 0 During exacerbation Number of efforts to obtain good quality spirometry Time needed to obtaing good quality spirometry Figure 1. Number of efforts needed to achieve a good quality spirometry: stable state vs. exacerbation Figure. Time needed to obtain a good quality spirometry: stable state vs. exacerbation Number of efforts to obtain spirometry-stable perio p=0.0 No exacerbations or more exac. Number of efforts to obtain spirometry during exac p=0.0 1 No exacerbations or more exac. Figure. Number of efforts needed to obtain a good quality spirometry in stable state of disease: infrequent exacerbators vs. frequent exacerbators Figure. Number of efforts needed to obtain a good quality spirometry during exacerbation: infrequent exacerbators vs frequent exacerbators In 1 patients (1%) presenting with exacerbation, a good quality spirometry could not be obtained. The causes were: cough, dyspnea, increased fatigue. These patients had a good quality spirometry recorded previously, during stable the state of the disease. The other patients (%) were able to perform the test at the presentation for exacerbation. The number of efforts needed to achieve a good quality spirometry session in these patients was higher during exacerbation (.±1. efforts) than during the previous stable period (.±0. efforts), p=0.001 as shown in Figure 1. Regarding the time required to obtain a spirometry session (Figure ), it was higher during the exacerbation (.±1. minutes) than during the stable period (. ± 1. minutes) (p=0.001). According to the history of exacerbations in the past year, patients were divided in a group of frequent exacerbators (two or more per year): patients (1%), and a group of infrequent exacerbators (less than two per year): patients (%). Actually, these patients had no exacerbation in the past year. The spirometries obtained during a stable state of disease had similar qualities in the two groups: infrequent exacerbators needed a mean of. efforts to achieve acceptable spirometries, while the frequent exacerbators needed a mean of. efforts (Figure ). The difference is not statistically significant (p=0.0). Similarly, during the exacerbation, the patients with infrequent exacerbator phenotype needed.0 efforts to perform a spirometry, compared with frequent exacerbators that needed. efforts (Figure ). The difference is not statistically significant (p=0.0). When we analyzed the time required to carry out a spirometry during the stable period of disease, it took 0 VOL. No. /01

Pneumologia REVISTA SOCIETĂŢII ROMÂNE DE PNEUMOLOGIE Time needed to obtain spirometry-stable period p=0.0 No exacerbations or more exac. Time needed to obtain spirometry during exac. p=0.1 No exacerbations or more exac. Figure. Time needed to obtain a good quality spirometry session in stable state: infrequent exacerbators vs. frequent exacerbators Figure. Time needed to perform spirometry during exacerbation: infrequnt exacerbators vs. frequent exacerbators.1 minutes for infrequent exacerbators to perform the tests, versus.0 minutes for frequent exacerbators (Figure ), with no significant difference (p=0.0). Similar time periods, with no statistically significant differences, were needed to get the acceptable spirometry during exacerbations:. minutes for infrequent exacerbators versus. minutes for frequent exacerbators, p=0.1 (Figure ). Discussions Spirometry is an essential tool in the diagnosis of COPD, needed to confirm the clinical suspicion. In clinical practice, only few patients (about 0%) have the COPD diagnosis confirmed by spirometry (). Moreover, it is generally considered that COPD is a severely underdiagnosed condition, with an estimation of % or up to 0% of patients not being diagnosed (1). It is expected that some of these patients will be diagnosed for the first time in a respiratory department on the occasion of an exacerbation. The general assumption is that patients will not be able to perform a reliable spirometry at the moment of an exacerbation and, if they still do it, the values obtained would not be reliable for evaluating the severity of the disease. GOLD guidelines state that spirometry should be performed when the patient is stable and free from infections (). In real life, this restriction may not be operational. Some of these patients are probably never free of respiratory infections, while some will perform their first spirometry on the occasion of their first exacerbation. The guideline recommendation is based on the assumption that during infection or exacerbation, the spirometric parameters may be lower than the personal best values of the patient that can be recorded in stable state of the disease. Thus, spirometries performed during an exacerbation might induce the inclusion of the patient in a more severe GOLD stage than in stable state. Several previous studies tried to define if there really existed a significant change in FEV1 and FVC after the resolution of the exacerbation. A study conducted on a group of 1 COPD patients compared the spirometry performed at discharge after hospitalization for exacerbation of COPD with the spirometry performed weeks later. No significant differences have been recorded one month after discharge, registering variations of a GOLD level classification with one step up or down (). Another study demonstrated that changes in lung function associated with exacerbations were small, compared to previous records: a fall of FEV1 by ml, and FVC by ml (1). In a study that assessed the respiratory function in the first days of admittance for asthma or COPD exacerbation, only percent of the functional lung tests were acceptable, their quality being related to the time elapsed from the onset of the exacerbation (1). This study suggested that performing a spirometry shortly after the onset of an exacerbation could be associated with the inability to produce adequate spirometric traces. Our study intended to check whether a spirometry performed at the onset of a COPD exacerbation can produce valid data, according to the ERS/ATS criteria. However, in these patients a previous functional test was available. All the patients included in the study were able to perform reproducible tests in stable state, but during exacerbation some patients (1%) could not perform good efforts, due to cough or dyspnea, while most of them ( patients; %) were able to produce valid results, but in significantly more time and with a higher number of efforts. Our patients performed the spirometry on the first day of presentation to the physician, before the initiation of exacerbation treatment (increased bronchodilation, antibiotics, systemic corticosteroids). In the previous studies published, the spirometry was performed at discharge (1) or after five days of hospitalization (1). VOL. No. /01 1

The fact that it is possible to achieve acceptable pulmonary function tests in patients presenting with a COPD exacerbation in a medical service was found by another study conducted by White. From the 1 patients presented with an acute exacerbation of COPD in primary care, patients (.1%) were able to produce at least one technically acceptable spirometry trace at presentation; 0 patients (.%) managed to produce acceptable traces at all time points (1). In our study, % of patients could perform good quality spirometries in the first day of admittance for COPD exacerbation, which is higher than previously reported (% in the study of Rea, and.% in the study of White) (1,1). This might be due to the setting of a research center, the preselection of patients for a clinical trial, involving a supplemental attention of the technicians for best spirometry procedures to the fact that the patients were trained and all had performed previous spirometry before. Our study highlighted that during exacerbation it was more difficult to obtain a good quality spirometry, as compared to stable period. Also, the time needed to perform a spirometry was longer in exacerbation versus stable state. However, performing a good spirometry is possible in most cases. The spirometries performed under such conditions may be useful for everyday clinical care, allowing the spirometric confirmation of obstruction and COPD diagnosis, especially in a patient at his/her first presentation for the disease. Spirometry can act as a filter, separating patients with COPD from those with other respiratory disease misdiagnosed as COPD exacerbation. The values of FEV1 and FVC may reflect accurately the severity of the disease. Spirometries during exacerbation can be useful for research, bringing new insights into the effect of exacerbation on lung volumes. This could hypothetically launch the idea of a functional classification of COPD exacerbation (mild, moderate or severe) according to lung volume lost on this occasion. Another use could be the evaluation of novel treatments for exacerbation on lung function. Our attempt to check if another criterion for COPD severity, the frequent exacerbator phenotype, could influence the quality of the function tests showed that this phenotype is not correlated separately with the quality of spirometry. Most likely, the higher difficulty to obtain good tests had other causes, related to the exacerbation itself: the degree of thoracic hyperinflation, cough, impairment of respiratory muscle strength, coexistence of infection, or other. One limitation of our study was the inclusion in the study group only of patients with mild/moderate exacerbation and the exclusion of patients with severe exacerbation. Conclusions In exacerbation, compared to a period of stable COPD, it was more difficult to obtain good quality spirometry, needing more time and more efforts. The percentage of patients that could anyway perform reproducible tests was higher than in previous studies, possibly due to the setting of the study, in a research center. A similar quality of spirometry has been observed in patients with frequent exacerbations, as in patients without exacerbations in the previous year, the phenotype of frequent exacerbator did not have any influence on the spirometry quality. n References 1. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 00; :.. Donaldson GC, Wedzicha JA. COPD exacerbations? 1: Epidemiology. Thorax. 00; 1:1 1.. Wier LM, Elixhauser A, Pfuntner A, Au DH. Overview of Hospitalizations among Patients with COPD, 00. HEALTHCARE COST AND UTILIZATION PROJECT. www.hcup-us.ahrq.gov/reports/statbriefs/sb.pdf, downloaded at March, 01. Global Strategy for Diagnosis, Management, and Prevention of COPD, Updated 01.. Arne M, Lisspers K, Ställberg B, Boman G, Hedenström H, Janson C, Emtner M. How often is diagnosis of COPD confirmed with spirometry? Respir Med. 0 Apr; ():0-.. Anthonisen NR, Wright EC, Hodgkin JE. Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1 Jan; 1(1):1-0.. Burgel PR, Paillasseur JL, Dusser D et al. On behalf of the UPLIFT Study. Tiotropium might improve survival in subjects with COPD at high risk of mortality. Respir Res. 01; 1(1):.. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1; :1 0.. Pellegrino R, Viegi GVB, Crapo R, Burgos F, Casaburi R, Coates A, van der Grinten C, Gustafsson P, Hankinson J, Jensen R, Johnson D, MacIntyre N, McKay R, Miller M, Navajas D, Pedersen O, Wanger J. Interpretative strategies for lung function tests. Eur Respir J. 00; ():.. Miller M, Hankinson JVB, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, Van der Grinten C, Gustafsson P, Jensen R, Johnson D, MacIntyre N, McKay R, Navajas D, Pedersen O, Pellegrino R, Viegi G, Wanger J. Standardisation of spirometry. Eur Respir J. 00; ():1. 11. Wagner J, Clausen JL, Coates A et al. Standardization of the measurement of lung volumes. Eur Respir J. 00; : 11-. 1. Rea H, Kenealy T, Adair J, Robinson E, Sheridan N. Spirometry for patients in hospital and one month after admission with an acute exacerbation of COPD. Int J Chron Obstruct Pulmon Dis. 011; :- 1. Seemungal TAR, Hurst JR, Wedzicha JA. Exacerbation rate, health status and mortality in COPD a review of potential interventions. Int J Chron Obstruct Pulmon Dis. 00; : 0. 1. Seemungal TAR, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 000; 11:10 1. 1. Prieto Centurion V, Huang F, Naureckas ET, Camargo CA Jr, Charbeneau J, Joo MJ, Press VG, Krishnan JA. Confirmatory spirometry for adults hospitalized with a diagnosis of asthma or chronic obstructive pulmonary disease exacerbation. BMC Pulm Med. 01 Dec ; 1:. 1. White AJ, O Brien C, Hill SL, Stockley RA. Exacerbations of COPD diagnosed in primary care: changes in spirometry and relationship to symptoms. COPD. 00 Dec; ():1-. VOL. No. /01